|
1
|
Ringer L, Sirajuddin P, Tricoli L, Waye S,
Choudhry MU, Parasido E, Sivakumar A, Heckler M, Naeem A,
Abdelgawad I, et al: The induction of the p53 tumor suppressor
protein bridges the apoptotic and autophagic signaling pathways to
regulate cell death in prostate cancer cells. Oncotarget.
5:10678–10691. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Okamura S, Arakawa H, Tanaka T, Nakanishi
H, Ng CC, Taya Y, Monden M and Nakamura Y: p53DINP1, a
p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell.
8:85–94. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tomasini R, Samir AA, Pebusque MJ, Calvo
EL, Totaro S, Dagorn JC, Dusetti NJ and Iovanna JL: P53-dependent
expression of the stress-induced protein (SIP). Eur J Cell Biol.
81:294–301. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tomasini R, Samir AA, Vaccaro MI, Pebusque
MJ, Dagorn JC, Iovanna JL and Dusetti NJ: Molecular and functional
characterization of the stress-induced protein (SIP) gene and its
two transcripts generated by alternative splicing. SIP induced by
stress and promotes cell death. J Biol Chem. 276:44185–44192. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nowak J, Depetris D, Iovanna JL, Mattei MG
and Pebusque MJ: Assignment of the tumor protein p53 induced
nuclear protein 2 (TP53INP2) gene to human chromosome band 20q11.2
by in situ hybridization. Cytogenet Genome Res.
108:3622005.PubMed/NCBI
|
|
6
|
Tomasini R, Samir AA, Carrier A, Isnardon
D, Cecchinelli B, Soddu S, Malissen B, Dagorn JC, Iovanna JL and
Dusetti NJ: TP53INP1s and homeodomain-interacting protein kinase-2
(HIPK2) are partners in regulating p53 activity. J Biol Chem.
278:37722–37729. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weng W, Yang Q, Huang M, Qiao Y, Xie Y, Yu
Y, jing A and Li Z: c-Myc inhibits TP53INP1 expression via promoter
methylation in esophageal carcinoma. Biochem Biophys Res Commun.
405:278–284. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang PH, Motoo Y, Garcia S, Iovanna JL,
Pébusque MJ and Sawabu N: Down-expression of tumor protein
p53-induced nuclear protein 1 in human gastric cancer. World J
Gastroenterol. 12:691–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ito Y, Motoo Y, Yoshida H, Iovanna JL,
Takamura Y, Miya A, Kuma K and Miyauchi A: Decreased expression of
tumor protein p53-induced nuclear protein 1 (TP53INP1) in breast
carcinoma. Anticancer Res. 26:4391–4395. 2006.PubMed/NCBI
|
|
10
|
Gironella M, Seux M, Xie MJ, Cano C,
Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et
al: Tumor protein 53-induced nuclear protein 1 expression is
repressed by miR-155, and its restoration inhibits pancreatic tumor
development. Proc Natl Acad Sci USA. 104:16170–16175. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonazzi VF, Irwin D and Hayward NK:
Identification of candidate tumor suppressor genes inactivated by
promoter methylation in melanoma. Genes Chromosomes Cancer.
48:10–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ito Y, Motoo Y, Yoshida H, Iovanna JL,
Nakamura Y, Kuma K and Miyauchi A: High level of tumour protein
p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic
carcinoma of the thyroid. Pathology. 38:545–547. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Giusiano S, Baylot V, Andrieu C, Fazli L,
Gleave M, Iovanna JL, TarangerCharpin C, Garcia S and Rocchi P:
TP53INP1 as new therapeutic target in castration-resistant prostate
cancer. Prostate. 72:1286–1294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li WG and Wang HQ: Inhibitory effects of
Silibinin combined with doxorubicin in hepatocellular carcinoma; an
in vivo study. J BUON. 21:917–924. 2016.PubMed/NCBI
|
|
15
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Center MM and Jemal A: International
trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers
Prev. 20:2362–2368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
European association for the study of the
liver; European organisation for research and treatment of cancer,
. EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: A study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pinder SE, Brown JP, Gillett C, Purdie CA,
Speirs V, Thompson AM and Shaaban AM: Translational Subgroup of the
NCRI Breast Clinical Studies Group: The manufacture and assessment
of tissue microarrays: Suggestions and criteria for analysis, with
breast cancer as an example. J Clin Pathol. 66:169–177. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carrier A, Nguyen C, Victorero G,
Granjeaud S, Rocha D, Bernard K, Miazek A, Ferrier P, Malissen M,
Naquet P, et al: Differential gene expression in CD3epsilon- and
RAG1-deficient thymuses: Definition of a set of genes potentially
involved in thymocyte maturation. Immunogenetics. 50:255–270. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gommeaux J, Cano C, Garcia S, Gironella M,
Pietri S, Culcasi M, Pébusque MJ, Malissen B, Dusetti N, Iovanna J,
et al: Colitis and colitis-associated cancer are exacerbated in
mice deficient for tumor protein 53-induced nuclear protein 1. Mol
Cell Biol. 27:2215–2228. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taïeb D, Giusiano S, Sebag F, Marcy M, de
Micco C, Palazzo FF, Dusetti NJ, Iovanna JL, Henry JF, Garcia S, et
al: Tumor protein p53-induced nuclear protein (TP53INP1) expression
in medullary thyroid carcinoma: A molecular guide to the optimal
extent of surgery? World J Surg. 34:830–835. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giusiano S, Garcia S, Andrieu C, Dusetti
NJ, Bastide C, Gleave M, TarangerCharpin C, Iovanna JL and Rocchi
P: TP53INP1 overexpression in prostate cancer correlates with poor
prognostic factors and is predictive of biological cancer relapse.
Prostate. 72:117–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seux M, Peuget S, Montero MP, Siret C,
Rigot V, Clerc P, Gigoux V, Pellegrino E, Pouyet L, N'Guessan P, et
al: TP53INP1 decreases pancreatic cancer cell migration by
regulating SPARC expression. Oncogene. 30:3049–3061. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Seillier M, Peuget S, Gayet O, Gauthier C,
N'Guessan P, Monte M, Carrier A, Iovanna JL and Dusetti NJ:
TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family
proteins through the LC3-interacting region (LIR) and promotes
autophagy-dependent cell death. Cell Death Differ. 19:1525–1535.
2012. View Article : Google Scholar : PubMed/NCBI
|
